Tafluprost
Tafluprost is a fluorinated prostanoid analog of latanoprost, a selective prostaglandin FP receptor agonist used as a preservative-free ophthalmic solution for reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. By increasing uveoscleral outflow of aqueous humor through FP receptor activation on ciliary smooth muscle, it reduces IOP without affecting aqueous humor production. The preservative-free formulation is particularly beneficial for patients with ocular surface disease.
分子量
452.5000 g/mol
LogP
4.50
TPSA
76.00 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
二维结构
Cite this structure
Embed this structure
SMILES
CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O
InChI
InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1
Molecular Formula
C25H34F2O5
HBD / HBA
2 / 7
可旋转键数
13
重原子数
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Tafluprost is a fluorinated prostanoid analog of latanoprost, a selective prostaglandin FP receptor agonist used as a preservative-free ophthalmic solution for reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. By increasing uveoscleral outflow of aqueous humor through FP receptor activation on ciliary smooth muscle, it reduces IOP without affecting aqueous humor production. The preservative-free formulation is particularly beneficial for patients with ocular surface disease.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Tafluprost is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1963683. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9868491. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tafluprost"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tafluprost/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tafluprost/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tafluprost/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tafluprost"></drugfyi-drug>